Arvinas Inc
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC ® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Holds 16.1x more cash than debt — a strong balance sheet.
Current Price
$10.51
+6.16%Arvinas Inc (ARVN) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Arvinas Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $262.60M. Gross profit (TTM) is $262.60M. EBITDA is $-75.20M. Earnings per share (EPS) is $-1.14. The P/E ratio is -8.35. Market capitalization is $675.00M.
Free cash flow (FCF) is $-275.70M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Arvinas Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
